Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Xu, Qingqing; Zhang, Suli; Wu, Chunlei; Xiong, Yüting; Niu, Jiamin; Li, Fengzhen; Zhu, Jiaquan; Shen, Lu; Zhu, Bin; Xing, Qinghe; Chen, Luan; Li, Mo; Li, Hua; Ge, Junbo; Qin, Shengying

doi:10.1097/fjc.0000000000001048

Cited by 3 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CYP2C9*2 (rs799853) and CYP2C9*3 (rs1057910) have been studied widely for their role in determining the efficacy of losartan among various populations [25,26], while rs2860905 has been commonly studied to determine the warfarin dose. Studies conducted on Caribbean Hispanic population and Han Chinese patients of valvular disease showed that rs2860905 variant is associated with warfarin sensitivity which could help in a more stable dosing of warfarin [27,28]. A recent study from Taiwan also concluded that CYP2C9 rs2860905 GG genotype increases the risk of ischemic stroke in the adult population suffering from atrial fibrillation [29].…”

Section: Discussionmentioning

confidence: 99%

Effect of CYP2C9 rs2860905 Polymorphism on the Efficacy of Losartan in Pakistani Hypertensive Patients

Haider,

Saeed,

Ikram

et al. 2023

CTO

View full text Add to dashboard Cite

Hypertension is a multifactorial disease characterized by high blood pressure in blood vessels. It is caused by the dysregulation of renin angiotensin aldosterone system (RAAS). It is a major risk factor for other metabolic diseases including cardiovascular diseases, diabetes, and others. Various RAAS targeting drugs such as losartan are prescribed as the first line therapy to treat hypertension. However, their efficacy varies among individuals owing to genetic variations in drug binding substrates or drug metabolizing enzymes, which convert the prodrug to active drug. CYP2C9 gene encodes for an enzyme which metabolizes losartan. Various studies have concluded that genetic variations in CYP2C9 affect the response of losartan due to the variation in its metabolism. Thus, the current study aimed to check the effect of CYP2C9 rs2860905 G>A polymorphism on the efficacy of losartan. For this purpose, a total of 48 subjects were selected and genotyped for rs2860905 polymorphism using in-house developed tetra-ARMS-PCR. The subjects were divided into responding (n=34) and non-responding (n=14) groups on the basis of their blood pressure after treatment with losartan. Statistical analysis demonstrated that rs2860905 GG genotype was more prevalent in the responding group as compared to the non-responding group (50% vs. 36%). Multinomial regression analysis showed that the carriers of GA or AA genotype did not respond to losartan treatment efficiently as compared to those of GG genotype. However, these results could not achieve statistical significance. To conclude, CYP2C9 rs2860905 G>A polymorphism does not affect the efficacy of losartan in Pakistani hypertensive subjects.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of CYP2C9 rs2860905 Polymorphism on the Efficacy of Losartan in Pakistani Hypertensive Patients

Haider,

Saeed,

Ikram

et al. 2023

CTO

View full text Add to dashboard Cite

show abstract

Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies

Zhao

Wang

et al. 2023

Clin Pharmacokinet

View full text Add to dashboard Cite

Polymorphism of the CYP2C9 and VKORC1 genes: a comment

Mungmunpuntipantip¹,

Wiwanitkit

2021

J. vasc. bras.

View full text Add to dashboard Cite

Dear editor, We would like to share ideas on "Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil. 1 " Tozato et al. studied polymorphisms of the CYP2C9 and VKORC1 genes, warfarin, and Time in Therapeutic Range (TTR) and concluded that "An association was observed between the polymorphisms and the warfarin doses taken by the patients. However, there was no association with adverse events or the time spent within the therapeutic range in this sample. 1 "The study drew conclusions that were not supported by its findings. It should only have concluded on the genetic epidemiology of polymorphisms. There are many confounding factors. An important consideration is the effect of other polymorphisms that are not assessed in the present study. Examples of these polymorphisms are CYP4F2 V433M, ABCB1, PROC, EPHX1, and SETD1A. 2,3

show abstract

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Abstract: Supplemental Digital Content is Available in the Text.

Cited by 3 publications

References 41 publications

Effect of CYP2C9 rs2860905 Polymorphism on the Efficacy of Losartan in Pakistani Hypertensive Patients

Effect of CYP2C9 rs2860905 Polymorphism on the Efficacy of Losartan in Pakistani Hypertensive Patients

Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies

Polymorphism of the CYP2C9 and VKORC1 genes: a comment

Contact Info

Product

Resources

About